Perfil
Klaus Dugi is currently the Chief Executive Officer at Vandria SA, Chairman at iNotify ApS, Director at AOBiome Therapeutics, Inc., and Venture Partner & Chief Medical Advisor at NanoDimension Management Ltd.
He was previously the Executive Vice President and Chief Medical Officer at Ferring Pharmaceuticals BV from 2017 to 2020 and the Chief Medical Officer at Boehringer Ingelheim Ltd.
from 2010 to 2015.
Cargos activos de Klaus Dugi
Empresas | Cargo | Inicio |
---|---|---|
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Director/Miembro de la Junta | 06/08/2018 |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | Consultor / Asesor | 01/01/2021 |
Vandria SA
Vandria SA Pharmaceuticals: MajorHealth Technology Vandria SA is a Swiss-based company that specializes in mitochondrial therapeutics. The company is based in Lausanne, Switzerland. The company is developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer that has shown to improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program that targets ferroptosis. The company was founded by Patrick Aebischer, Chris Rinsch, and Johan Auwerx in 2021 and has raised $20.60m in venture finance. Klaus Dugi has been the CEO of the company since 2021. | Director Ejecutivo | 01/10/2021 |
Antiguos cargos conocidos de Klaus Dugi.
Empresas | Cargo | Fin |
---|---|---|
Ferring Pharmaceuticals BV
Ferring Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals BV develops and manufactures pharmaceutical products. It manufactures pharmaceuticals within the fields of urology, gynecology, gastroenterology, and endocrinology. The company is headquartered in Moscow, Russia. | Presidente | 31/12/2020 |
Boehringer Ingelheim Ltd.
Boehringer Ingelheim Ltd. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Ltd. develops, manufactures, and distributes pharmaceutical products. It offers products for the treatment of chronic obstructive pulmonary disease, heart attack, secondary stroke prevention and treatment, high blood pressure, thromboembolic disease, Parkinson's disease, arthritis, and pain relief in cancer. The company was founded in 1885 and is headquartered in Bracknell, the United Kingdom. | Presidente | 31/12/2009 |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 5 |
---|---|
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | Finance |
Ferring Pharmaceuticals BV
Ferring Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals BV develops and manufactures pharmaceutical products. It manufactures pharmaceuticals within the fields of urology, gynecology, gastroenterology, and endocrinology. The company is headquartered in Moscow, Russia. | Health Technology |
Boehringer Ingelheim Ltd.
Boehringer Ingelheim Ltd. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Ltd. develops, manufactures, and distributes pharmaceutical products. It offers products for the treatment of chronic obstructive pulmonary disease, heart attack, secondary stroke prevention and treatment, high blood pressure, thromboembolic disease, Parkinson's disease, arthritis, and pain relief in cancer. The company was founded in 1885 and is headquartered in Bracknell, the United Kingdom. | Health Technology |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Vandria SA
Vandria SA Pharmaceuticals: MajorHealth Technology Vandria SA is a Swiss-based company that specializes in mitochondrial therapeutics. The company is based in Lausanne, Switzerland. The company is developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer that has shown to improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program that targets ferroptosis. The company was founded by Patrick Aebischer, Chris Rinsch, and Johan Auwerx in 2021 and has raised $20.60m in venture finance. Klaus Dugi has been the CEO of the company since 2021. | Health Technology |
- Bolsa de valores
- Insiders
- Klaus Dugi